Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.31
−$0.04 · -2.96%
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Previous close
$1.31
−$0.04 · -2.96%
Pre-market
$1.33
+$0.02 · +1.53%
Sep 8, 5:10 AM ET
Regular session · ET · Market data may be delayed.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $1.31
52-week range
Current $1.31
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
59
Mixed
Risk
84
Extreme Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Day range
Current $1.31
52-week range
Current $1.31
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 5M USD | — | 668K USD | — | — |
| Gross profit | −5M USD | — | −668K USD | — | — |
| Research and development | 176.07M USD | 200.93M USD | 142.72M USD | 104.75M USD | 212.78M USD |
| Selling, general, and administrative | 60.09M USD | 62.54M USD | 44.81M USD | 31.12M USD | 24.55M USD |
| Operating expenses | 236.16M USD | 263.46M USD | 187.53M USD | 135.87M USD | 237.32M USD |
| Interest income | 8.34M USD | 19.93M USD | 16.61M USD | 4.56M USD | — |
| Interest expense | 3.22M USD | — | — | — | — |
| Depreciation and amortization | 208K USD | 631K USD | 668K USD | 594K USD | 538K USD |
| Operating income | −241.16M USD | −263.46M USD | −188.19M USD | −135.87M USD | −237.32M USD |
| Net income | −236.93M USD | −243.79M USD | −235.93M USD | −130.9M USD | −237.31M USD |
Company facts updated Sep 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.53M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM3.33M0.00%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF1.81M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO1.17M0.01%14.7B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO930.36K0.01%17.4B USD0.06%$119.62+0.25%
iShares Biotechnology ETFIBB777.6K0.01%10.73B USD0.44%$211.92-0.88%
Schwab U.S. Small-Cap ETFSCHA625.39K0.00%22.93B USD0.03%$34.55+1.01%
iShares Micro-Cap ETFIWC477.4K0.03%1.49B USD0.60%$196.25+0.69%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
